Garzie the bait/reservoir idea was proposed by the authors of the study themselves, apparently. I agree with your concerns about
that idea though.
This is what it says in the Nature article:
"The authors have also carried out a 7-day toxicity study in rats, in which the compound showed good safety, and have plans to assess the efficacy of the compound in patients. Flightpath Biosciences, a start-up company co-founded by Lewis, is taking the lead in developing hygromycin A as the first dedicated therapeutic to treat Lyme disease. The authors also argue that, given its limited activity against non-spirochetal organisms, hygromycin A could be spread in large territories to target reservoirs of B. burgdorferi and potentially eradicate it in the environment."
From:
https://www.nature.com/articles/d41573-021-00180-x